<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471002</url>
  </required_header>
  <id_info>
    <org_study_id>5062</org_study_id>
    <nct_id>NCT01471002</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours &lt; 4cm in Patients Who Are Not Candidates for Partial Nephrectomy</brief_title>
  <acronym>CRYOREIN</acronym>
  <official_title>Prospective Study to Evaluate the Efficacy of Percutaneous Cryoablation for Renal Tumours &lt; 4cm in Patients Who Are Not Candidates for Partial Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to evaluate the oncologic efficacy of percutaneous cryoablation of&#xD;
      renal tumors smaller than 4 cm in patients with renal cancer that cannot be offered a partial&#xD;
      nephrectomy. The oncologic outcome will be assessed by the presence or absence of residue or&#xD;
      recurrence during a follow-up by MRI performed the first 12 months (M1, M3, M6, M12).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Suspicious contrast enhancement and progression in size of the cryolesion detected by MRI</measure>
    <time_frame>1 year</time_frame>
    <description>The success of cryoablation will be declared if the control at 1 year shows no suspicious contrast enhancement (the suspicious character is defined by significant contrast uptake (&gt;15%) and heterogeneous or nodular or crescent-shape contrast enhancement) and if the cryolesion is not progressing in size compared to early post-ablation control (M1).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Renal Tumors Less Than 4 cm</condition>
  <arm_group>
    <arm_group_label>Renal cancer without nephrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with renal cancer that cannot be offered a partial nephrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Galil Medical patented 17G Cryoablation Needles</intervention_name>
    <arm_group_label>Renal cancer without nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients should have the following characteristics:&#xD;
&#xD;
          -  About 75 years, or&#xD;
&#xD;
          -  Whatever the age:&#xD;
&#xD;
               -  A context of family-type tumor (VHL, hereditary carcinoma, tubulo-papillary ...);&#xD;
&#xD;
               -  or solitary kidney, when the tumor is not easily accessible for nephron-sparing&#xD;
                  surgery: Malignant centro-hilar or intra-parenchymal;&#xD;
&#xD;
               -  or in a local recurrence (single or multiple) after partial nephrectomy (within a&#xD;
                  limit of 3 tumors to be treated);&#xD;
&#xD;
               -  or in a subject with impaired renal function and therefore at risk of severe&#xD;
                  renal insufficiency (risk defined by a creatinine clearance below 30 ml / min by&#xD;
                  MDRD formula);&#xD;
&#xD;
               -  and who do not present any contra-indication for cryoablation treatment.&#xD;
&#xD;
        The tumor(s) should meet the following criteria:&#xD;
&#xD;
          -  Presence of one to three solid tumors of the native renal parenchyma with a largest&#xD;
             diameter less than (or equal to) 40 mm, which corresponds to a maximum volume of about&#xD;
             32 cc, as measured by MRI.&#xD;
&#xD;
          -  A preoperative MRI is essential since this technique presents a higher sensitivity.&#xD;
             This control will also give more consistency to the evaluation of the radiological&#xD;
             semiology at follow-up.&#xD;
&#xD;
          -  And its/their location(s) will be accessible to a percutaneous approach.&#xD;
&#xD;
        The search of metastases, including a thoracic CT scan, should be negative.&#xD;
&#xD;
        Exclusion Criter ia:&#xD;
&#xD;
          -  - Partial nephrectomy feasible in good technical and oncologic conditions in patients&#xD;
             under 75 years and in the absence of family tumors.&#xD;
&#xD;
          -  Contraindication to any form of sedation.&#xD;
&#xD;
          -  Irreversible coagulopathy&#xD;
&#xD;
          -  Tumor&gt; 4cm&#xD;
&#xD;
          -  Contraindication to MRI or gadolinium (proven allergy). NB: Patients with a glomerular&#xD;
             filtration rate below 30 ml/min/1, 73 m2 will be injected with a single dose of the&#xD;
             macrocyclic gadolinium with the highest thermodynamic stability (Dotarem or Prohance),&#xD;
             given the united recommendations of AFSSAPS and EMA (European Medicines Agency) [45].&#xD;
             On the contrary, the linear molecules of gadolinium, due to their lower stability,&#xD;
             will be contra-indicated because of the risk of systemic nephrogenic fibrosis (FNS).&#xD;
&#xD;
          -  Recurrence on the same location after a procedure performed out of the thermoablation&#xD;
             protocol.&#xD;
&#xD;
          -  Biopsy proven benign tumor&#xD;
&#xD;
          -  Predominantly cystic tumor, defined by a necrotic content constituting over one third&#xD;
             of tumor volume&#xD;
&#xD;
          -  Presence of endo-venous extension, of proven secondary extensions, visceral or in the&#xD;
             lymph nodes (especially lung). In this regard, a thoracic CT scan will be routinely&#xD;
             required before treatment, according to the recommendations of urological societies.&#xD;
&#xD;
          -  Psychiatric disorders and adults under guardianship&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Minor patients&#xD;
&#xD;
          -  Legal safeguard&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshin GANGI, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 3, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

